Trial Information
A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL
Inclusion Criteria:
- Histologically confirmed CD20+ diffuse large B-cell lymphoma or follicular lymphoma
- Treatment with MabThera/Rituxan as per locally approved China package insert
- Documented patient with medical records
Exclusion Criteria:
- Previous treatment for diffuse large B-cell lymphoma or follicular lymphoma
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety: Incidence of adverse events
Outcome Time Frame:
4.5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
China: Ministry of Health
Study ID:
ML25435
NCT ID:
NCT01340443
Start Date:
January 2011
Completion Date:
April 2016
Related Keywords:
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse